Literature DB >> 8100206

Effects of serotonin on rat ileocolonic transit and fluid transfer in vivo: possible mechanisms of action.

L Oosterbosch1, M von der Ohe, M A Valdovinos, L J Kost, S F Phillips, M Camilleri.   

Abstract

The aim was to investigate the action of serotonin (5HT) on function of the ileocolonic junction (ICJ) in vivo. In anaesthetised rats, models were developed to study the effects of intra-aortic (ia) serotonin on ileocolonic and colonic transit, and the effects on transit of a number of 5HT receptor antagonists. In the first series of experiments, a bolus of saline labelled with 99mTc DTPA was instilled 20 cm proximal to the ICJ and transit was assessed three hours later by the geometric centre of the spread of isotope. In the second series, similar techniques were used on the postcaecal colon and transit assessed two hours later. In the third series of experiments, the effects of ia 5HT on ileal net fluid flux was evaluated by standard perfusion experiments with 14C polyethylene glycol (PEG) 4000 as a non-absorbable marker in rat plasma-like electrolyte solution. Compared with ia saline, 5HT accelerated ICJ transit significantly (p < 0.05). This acceleration was comparable with the effect of ia bethanechol. The effects of 5HT on ICJ transit were inhibited by the intraperitoneal (ip) infusion of atropine, the 5HT receptor antagonists, methysergide, ketanserin, zacopride, and the 5HT4 agonist, SC53116. Methysergide, zacopride, and SC53116 given with ia 5HT slowed ICJ transit to rates below those of ia saline alone. When these same agents were given together with ia saline, the ICJ transit was not significantly altered. Serotonin, at the dose that accelerated ICJ transit, did not significantly alter colonic transit or ileal fluid transport. In conclusion, 5HT is a potent pharmacological stimulant of transit across the rat ICJ in vivo; the action of 5HT is mediated partly through muscarinic neurones and several 5HT receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100206      PMCID: PMC1374264          DOI: 10.1136/gut.34.6.794

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  Release of endogenous 5-hydroxytryptamine from resting and stimulated enteric neurons.

Authors:  M D Gershon; H Tamir
Journal:  Neuroscience       Date:  1981       Impact factor: 3.590

2.  Is 5-HT a mediator in the motor control of the feline pylorus?

Authors:  P Lidberg; A Dahlström; H Ahlman
Journal:  Scand J Gastroenterol       Date:  1984-05       Impact factor: 2.423

3.  The sites of action of 5-hydroxytryptamine in nerve-muscle preparations from the guinea-pig small intestine and colon.

Authors:  M Costa; J B Furness
Journal:  Br J Pharmacol       Date:  1979-02       Impact factor: 8.739

4.  Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms.

Authors:  K H Buchheit; G Engel; E Mutschler; B Richardson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-03       Impact factor: 3.000

5.  Gastrointestinal and metabolic function in patients with the carcinoid syndrome.

Authors:  J M Feldman; J W Plonk
Journal:  Am J Med Sci       Date:  1977 Jan-Feb       Impact factor: 2.378

6.  Effects of serotonin on the internal anal sphincter: in vivo manometric study in rats.

Authors:  M Goldberg; M Hanani; S Nissan
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

7.  Accurate measurement of intestinal transit in the rat.

Authors:  M S Miller; J J Galligan; T F Burks
Journal:  J Pharmacol Methods       Date:  1981-11

8.  Multiple 5-hydroxytryptamine receptors on feline ileum and ileocecal sphincter.

Authors:  A Ouyang; S Cohen
Journal:  Am J Physiol       Date:  1983-04

9.  Mechanisms of the relaxations induced by 5-hydroxytryptamine on the rat isolated caecum.

Authors:  M O Uguru; S O Bamgbose
Journal:  J Pharm Pharmacol       Date:  1986-02       Impact factor: 3.765

10.  Elevated concentrations of substance P and 5-HT in plasma in patients with carcinoid tumors.

Authors:  P C Emson; R F Gilbert; H Martensson; A Nobin
Journal:  Cancer       Date:  1984-08-15       Impact factor: 6.860

View more
  6 in total

1.  Gastrointestinal endocrine cells in an animal model for human type 2 diabetes.

Authors:  A Spångéus; M Kand; M El-Salhy
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

2.  Anti-mitogenic and apoptotic effects of 5-HT1B receptor antagonist on HT29 colorectal cancer cell line.

Authors:  Ramin Ataee; Soheila Ajdary; Mohammadreza Zarrindast; Mehdi Rezayat; Mohammad Reza Hayatbakhsh
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-21       Impact factor: 4.553

3.  Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.

Authors:  M R von der Ohe; R B Hanson; M Camilleri
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

4.  Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function.

Authors:  Kara Gross Margolis; Zhishan Li; Korey Stevanovic; Virginia Saurman; Narek Israelyan; George M Anderson; Isaac Snyder; Jeremy Veenstra-VanderWeele; Randy D Blakely; Michael D Gershon
Journal:  J Clin Invest       Date:  2016-04-25       Impact factor: 14.808

5.  Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study.

Authors:  Sheharyar A Qureshi; Nicola Burch; Maralyn Druce; John G Hattersley; Saboor Khan; Kishore Gopalakrishnan; Catherine Darby; John L H Wong; Louise Davies; Simon Fletcher; William Shatwell; Sharmila Sothi; Harpal S Randeva; Georgios K Dimitriadis; Martin O Weickert
Journal:  BMJ Open       Date:  2016-05-04       Impact factor: 2.692

6.  Nicotinamide adenine dinucleotide replenishment rescues colon degeneration in aged mice.

Authors:  Xudong Zhu; Weiyan Shen; Ying Wang; Amit Jaiswal; Zhenyu Ju; Qinsong Sheng
Journal:  Signal Transduct Target Ther       Date:  2017-07-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.